container

Global Market for Women’s Health Therapeutics Expected to Reach $22.5 Billion in 2018; Postmenopausal Osteoporosis Claims 53% Market Share

According to a new report from BCC Research,the global market for women’s health therapeutics is expected to grow to $22.5 billion by 2018, with a five-year compound annual growth rate (CAGR) of 3.5%. The postmenopausal osteoporosis therapeutics segment leads the global market, claiming 53% market share.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
SAMPLE FIGURE GLOBAL MARKET FOR WOMEN’S HEALTH THERAPEUTICS, 2012-2018 ($ MILLIONS)

SAMPLE FIGURE GLOBAL MARKET FOR WOMEN’S HEALTH THERAPEUTICS, 2012-2018 ($ MILLIONS)

Global Market for Women’s Health Therapeutics Expected to Reach $22.5 Billion in 2018

Wellesley, Mass., (PRWEB) May 29, 2014

BCC Research (http://www.bccresearch.com) reveals in its new report, Therapeutics for Women's Health: Technologies and Global Markets, the global market for women’s health therapeutics is expected to grow to $22.5 billion by 2018, with a five-year compound annual growth rate (CAGR) of 3.5%. The postmenopausal osteoporosis therapeutics segment leads the global market, claiming 53% market share.

Women’s health issues have gained significant market attention recently as a result of disease pattern and treatment differences between men and women. The U.S. segment, by far the largest- and fastest-growing regional market, is expected to reach $13.5 billion by 2018, registering a CAGR of 4.7%.

The European and Japanese markets are projected to approach $7.5 billion and nearly $1.4 billion, respectively, by 2018, at CAGRs of 1.7% and 1.8%.

Currently, postmenopausal osteoporosis dominates the global market for women’s health therapeutics and technologies, followed by menopause, endometriosis, and polycystic ovary syndrome, which claim 30%, 14%, and 4% of the total market, respectively.

“Patent expiry is one of the key challenges for the growth of this market and has resulted in a slowdown in recent few years due to patent expiries of blockbusters such as Evista, the Premarin family, Actonel, and other drugs,” says BCC Research biotechnology analyst Dr. Ritu Thakur Dangi. “However, the launch of novel therapies (e.g., elagolix, odanacatib, Femitra, among others) in the late-stage pipeline has the strong potential to drive the market during the forecast period.”

therapeutics for Women's Health: Technologies and Global Markets provides an overview of the global market for women’s health therapeutics. It includes analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.

Editors and reporters who wish to speak with the analyst, should contact Steven Cumming at steven.cumming(at)bccresearch(dot)com.

About BCC Research

BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years we've helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key competitors. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Our clients include the top companies in industries around the world as well as universities, business schools, start-ups, consulting firms and investment companies. BCC Research is a unit of Eli Research LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern time), or email information(at)bccresearch(dot)com.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49-2 Walnut Park, Wellesley, MA 02481, Telephone: (+1) 781-489-7301; Email: editor(at)bccresearch(dot)com as the source and publisher. Thank you.


Contact